The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new

Publication date: April 2019Source: Best Practice &Research Clinical Endocrinology &Metabolism, Volume 33, Issue 2Author(s): Philippe Chanson, Dominique MaiterPrevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced gonadotropic failure involves kisspeptin neurons. Prolactinomas in males are larger, more invasive and less sensitive to dopamine agonists (DAs). Macroprolactin, responsible for pseudohyperprolactinemia is a frequent pitfall of prolactin assay.DAs still represent the primary therapy for most prolactinomas, but neurosurgery has regained interest, due to progress in surgical techniques and a high success rate in microprolactinoma, as well as to some underestimated side effects of long-term DA treatment, such as impulse control disorders or impaired quality of life. Recent data show that the suspected effects of DAs on cardiac valves in patients with prolactinomas are reassuring. Finally, temozolomide has emerged as a valuable treatment for rare cases of aggressive and malignant prolactinomas that do not respond to all other conventional treatments.
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
FDA has granted Emergency Use Authorization (EUA) to Battelle's CCDS Critical Care Decontamination System for processing up to 80,000 respirator masks per system each day. CCDS employs concentrated, vapor-phase hydrogen peroxide (VPHP) for decontamination. The system has been validated to decontaminate masks of SARS-CoV-2, the company reported. The masks are placed on shelves inside a container, and a portable, external VPHP system is hooked up to the outside of container. The system was first envisioned by Battelle as part of a study commissioned by FDA in 2015. That study involved determining the feasibility of N95 respi...
Source: MDDI - Category: Medical Devices Authors: Tags: Sterilization Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Jorge A Alfaro-Murillo, Marí L Ávila-Agüero, Meagan C Fitzpatrick, Caroline J Crystal, Luiza-Helena Falleiros-Arlant, Alison P Galvani
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Stephen W Russell, Brian T Garibaldi, Andrew Elder, Abraham Verghese
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s):
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Fathiah Zakham, Olli Vapalahti, Hilal A Lashual
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Renato D Lopes, Claudio Gimpelewicz, John J V McMurray
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Genichi Sugihara, Nori Takei
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Gorka Orive, Unax Lertxundi
Source: The Lancet - Category: General Medicine Source Type: research
More News: Brain | Cancer & Oncology | Endocrinology | Epidemiology | Neurology | Neurosurgery | Temodar